A recent study has shown a low intra-patient heterogeneity and temporal changes in PD-L1 expression using paired synchronous and metachronous tumor specimens of 39 NSCLC patients treated at Memorial Sloan Kettering Cancer Center [38] supporting the reliability of such biomarker for clinical use. Here, CD274 is linked to non-small cell lung carcinoma.